Spine News and Research

RSS

Pre-treatment quality-of-life scores predict malignancy in patients with pancreatic disease

Quality-of-life measures used routinely to assess treatment outcomes for patients with pancreatic disease may be used to predict both malignancy and survival for those patients, according to a study by Henry Ford Hospital.

5 May 2010

Boston Scientific commences enrollment in trial comparing SCS to spine reoperation in FBSS patients

Boston Scientific Corporation today announced the start of patient enrollment in the EVIDENCE Clinical Trial, which compares the therapeutic effectiveness and cost effectiveness of spinal cord stimulation (SCS) therapy to spine reoperation in patients with failed back surgery syndrome (FBSS). The first patient was enrolled by Joseph Buwembo, M.D. and Krishna Kumar, M.D., F.R.C.S.C., at Regina General Hospital in Regina, Saskatchewan, Canada.

4 May 2010

$Osteoporosis screening can reduce risk of future fractures$

Osteoporosis screening can reduce risk of future fractures

One in two women in the United States will have an osteoporosis-related fracture in her lifetime. However, according to a review article published in the May 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), only a few of these women will be tested and treated for osteoporosis, which if identified and treated, could dramatically decrease their risk of future fractures.

4 May 2010

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a study published online today in Blood, the journal of the American Society of Hematology, researchers present positive results of a Phase II clinical trial of eliglustat tartrate, an oral therapy in development to treat Gaucher disease.

4 May 2010

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

3 May 2010

SGB procedure holds potential promise for PTSD treatment

Walter Reed Army Medical Center in Bethesda, MD, has published case reports detailing the successful treatment of combat-related post-traumatic stress disorder with a stellate ganglion block.

3 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

A major research initiative to optimize quality of life for cancer survivors

At the age of 12, she was diagnosed with spinal cord cancer, with a nasty tumor sitting at the very base of her spinal cord and getting entangled with spinal nerves.

30 Apr 2010

New report evaluating use of SBRT in lung cancer treatment released

The American Society for Radiation Oncology has released its Emerging Technology Committee's report evaluating the use of stereotactic body radiotherapy in lung cancer treatment.

29 Apr 2010

RTI Biologics reports revenues of $37.8M for first-quarter 2010

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, reported operating results for the first quarter ending March 31, 2010

29 Apr 2010

USPTO issues new patent to Applied Spine Technologies

Applied Spine Technologies, Inc. www.appliedspine.com, a medical device company focused on motion preservation of the lumbar spine, has been awarded a new patent titled "Spinal Stabilization Device with Weld Cap".

29 Apr 2010

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month.

28 Apr 2010

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana.

28 Apr 2010

SI-BONE to present iFuse MIS procedure at WCMISST 2010

SI-BONE, Inc., a medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint today announced that iFuse initial post-market clinical experience will be presented at upcoming 2010 minimally invasive spine surgery meetings.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

Tel Aviv University researcher maps drug target to wipe pain away

In most cases of chronic pain -- lingering pain that never seems to go away after accidents or prolonged illnesses ― no pill exists to dull the hurt. Billions of dollars are lost every year in sick days taken to alleviate chronic pain, and as much money is spent by the healthcare system to diagnose what's wrong.

27 Apr 2010

VertiFlex enrolls 100 patients in Superion Interspinous Spacer IDE clinical trial

VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 100 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).

27 Apr 2010

Global Health Partner reports 12% increase in revenues for first-quarter 2010

The strong growth within our Service Line Bariatrics continues, above all at our oldest clinic Bariatric Center Stockholm. Our arrhythmia clinic Arrhythmia Center Stockholm has also had good capacity utilization during the quarter and continues to generate better than expected results.

26 Apr 2010

McGill researchers receive $1.7M for 10 cutting-edge research projects

Ten McGill University researchers received an important boost today, by way of the announcement of $1.7 million in new funding awarded through the Canada Foundation for Innovation's Leaders Opportunity Fund. "CFI investments are critical for our research leaders, to ensure that their research remains innovative and second to none," said Dr. Rima Rozen, Interim Vice-Principal (Research and International Relations) at McGill.

24 Apr 2010